Structure Therapeutics, Inc. (GPCR)
41.25
+3.48
(+9.21%)
USD |
NASDAQ |
Jun 09, 16:00
41.25
0.00 (0.00%)
After-Hours: 20:00
Structure Therapeutics Research and Development Expense (Quarterly) : 66.71M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.51B |
| Novo Nordisk A/S | 1.610B |
| Viking Therapeutics, Inc. | 150.15M |
| Pfizer Inc. | 2.452B |
| Tarsus Pharmaceuticals, Inc. | 22.35M |